Summary
Eli Lilly and Company's first quarter 2007 report shows a significant increase in net sales, up 14% to $4.23 billion, driven by strong performance from Cymbalta, Zyprexa, and the recently acquired Cialis (following the ICOS Corporation acquisition). However, net income and earnings per share saw a substantial decrease of 39% to $508.7 million and $0.47, respectively. This decline is primarily attributed to significant one-time charges, including $303.5 million for acquired in-process research and development from the ICOS acquisition and $123.0 million for asset impairments and restructuring. The company also provided updated financial guidance for 2007, expecting sales growth in the low double digits and earnings per share between $2.63 and $2.73.
Key Highlights
- 1Net sales increased by 14% year-over-year to $4.23 billion, fueled by key products like Cymbalta, Zyprexa, and the newly acquired Cialis.
- 2Net income decreased by 39% to $508.7 million, largely impacted by significant charges related to the ICOS acquisition and restructuring activities.
- 3The acquisition of ICOS Corporation for approximately $2.3 billion was completed in January 2007, bringing full ownership of Cialis and adding $628.4 million in goodwill.
- 4Research and development expenses increased by 13% to $834.2 million, reflecting continued investment in pipeline development and costs associated with regulatory setbacks like Arxxant.
- 5Marketing and administrative expenses rose by 17% to $1.34 billion, primarily due to the ICOS acquisition, increased marketing efforts for key products, and higher litigation costs.
- 6The company settled a substantial majority of US Zyprexa product liability claims, agreeing to settle approximately 28,500 claims, with ongoing litigation for the remaining ~1,300 plaintiffs.
- 7Eli Lilly is facing ongoing government investigations related to marketing and promotional practices for Zyprexa and other products, with potential for significant financial impact.